HDAC inhibitors as Novel Anti-Cancer therapeutics

Recent Patents on Anti-Cancer Drug Discovery

Volumn 10, Issue 2, 2015, Pages 145-162

  De Souza, Cristabelle ^b   Chatterji, Biswa P ^a  

^a ST XAVIER S COLLEGE   (India)

^b TATA MEMORIAL HOSPITAL   (India)

Author keywords

Cancer; Epigenetics; HDAC inhibitors; Histone deacetylases (HDAC s); Isoform specific; Tumor

Indexed keywords

ABEXINOSTAT; BELINOSTAT; ENTINOSTAT; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MOCETINOSTAT; PANOBINOSTAT; ROMIDEPSIN; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE REGULATION; CELL PROLIFERATION; DNA METHYLATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETIC REPRESSION; GENE REPRESSION; HUMAN; IC50; NEOPLASM; PATENT; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG DESIGN; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATENTS AS TOPIC;

EID: 84930894083     PISSN: 15748928     EISSN: 22123970     Source Type: Journal    
DOI: 10.2174/1574892810666150317144511     Document Type: Article

References (77)

1. [1] Hanahan D, Weinberg R. Hallmarks of Cancer: The next generation. Cell 2011; 144(5): 646-74.
2. [2] Chorawala M, Oza P, Shah G. Mechanisms of anticancer drugs resistance: An overview. Int J Pharmaceut Sci Drug Res 2012; 4(1):1-9.
3. Medicine Net. Available at: http://www.medicinenet.com/script/main/art.asp?articlekey=21716 (Accessed on: August 26th, 2014).
4. [4] Vidali G, Gershey EL, Allfrey VG. Vincent Allfrey’s work on histone acetylation. J Biol Chem 2012; 287(3): 2270-1.
5. [5] Allfrey V, Faulkner R, Mirsky A. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis; Proc Natl Acad Sci USA 1964; 51(5): 786-94.
6. [6] Goldberg A, Allis C, Bernstein E. Epigenetics: A landscape takes shape. Cell 2007; 128(4): 635-8.
7. [7] Lu D. Epigenetic modification enzymes: Catalytic mechanisms and inhibitors. Acta Pharmaceutica Sinica 2011; 3(3): 141-9.
8. [8] Fischle W, Dequiedt F, Hendzel M, Guenther M, Lazar M, Voelter W, et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Molecular Cell 2002; 9(1): 45-57.
9. [9] De Ruitjer A, Van Gennip A, Caron H, Kemp S, Van Kuilenburg A. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J 2003; 370(3): 737.
10. [10] Thiagalingam S, Cheng K, Lee H, Mineva N, Thiagalingam A, Ponte J. Histone deacetylases: Unique players in shaping the epigenetic histone code. Ann NY Acad Sci 2003; 983(1): 84-100.
11. [11] Dokmanovic M, Clarke C, Marks P. Histone deacetylase inhibitors: Overview and perspectives. Mol Cancer Res 2007; 5(10): 981-9.
12. [12] Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang SW. Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther 2010; 10(6): 935-54.
13. [13] Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265(28):17174-9.
14. [14] Richon V, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind R, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Nat Acad Sci 1998; 95(6): 3003-7.
15. [15] Mann B, Johnson J, Cohen M, Justice R, Pazdur R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12(10): 1247-52.
16. [16] FDA Approves Drug Treatment for Rare Cancer Cutaneous T-cell lymphoma affects about 1,500 Americans annually (2009). Available: at:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm189629.htm (Accessed on: August 24th, 2014).
17. [17] Jain D, Singh A, Patel V, Sharma PC, Gupta A, Sharma A, et al. Hydroxamic acid based Histone Deacetylase inhibitors: Present and future prospectives as anticancer agent. Int J Pharm Pharm Sci 2014; 6(4): 648-50.
18. [18] Karagiannis TC, El-Osta A. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia 2007 21: 61-5.
19. [19] Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: Targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006; 33: 407-20.
20. [20] Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nature Rev 2006; 6: 714-27.
21. [21] Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol 2012; 6(6): 579-89.
22. [22] Giannini G, Cabri W, Fattorusso C, Rodriguez M. Histone deacetylase inhibitor in the treatment of cancer: overview and perpectives; Future Med Chem 2012; 4(11): 1439-60.
23. [23] Ververis K, Hiong, A, Karagiannis TC, Licciardi PV. Histone deacetylase inhibitors (HDACI’s): Multi-targeted anticancer agents; Biologics 2013; 7: 47-60.
24. [24] Srinivas, A.S., Narasimhan, K., Manikandan, L., Rajagopal, S., Selvakumar, T., Reddy, G. Novel HDAC inhibitors. US20070088043 (2007).
25. [25] Balasubramanian, G., Thanasekaran, P., Rajagopal, S., Kuppusamy, B., Kachhadia, V., Radhakrishnan, V., Velaiah, S., Narayanan, S., Bhonde, M., Rajendran, P., Rajagopal, S. Novel bridged cyclic compounds as histone deacetylase inhibitors. US20110212943 (2011).
26. [26] Francoise, L., Marconnet-Decrane, B., Francoise, S., Gaurrand, D., Angibaud, P.R. Pyridine and Pyrimidine derivatives as inhibitors of histone deacetylase. US008114876 (2012).
27. [27] Cai, X., Qian, C., Gould, S., Zhai, H. Multi-functional small molecules as anti-proliferative agents. US20080221132 (2008).
28. [28] Georg, F., Herting, S., Koerner, A., Kubbies, P., Limberg, P., Ulrich, T. Thiophene hydroxamic acid derivatives and their use as HDAC inhibitors. US007423060 (2008).
29. [29] Horinouchi, S.Y., Komatsu, T., Nishino, M.N., Yoshida, M. Novel cyclic tetrapeptide derivatives and medicinal use thereof. EP1010705 (2000).
30. [30] Leblond, B., Beausoleil, E. Tricyclic hydroxamate and benzamide derivatives, compositions and methods. US007923579 (2011).
31. [31] Gomez, V., Dominguez, S., Tabraue, C. Novel derivatives of Phthalimide as histone deacetylase inhibitors. EP2045239 (2009).
32. [32] Finn, P.W., Kalvinsh, I., Loza, E., Andrianov, V., Habarova, O., Lolya, D., Piskunova, I. Carbamic acid compounds comprising a Bicyclic Heteroaryl group as HDAC inhibitors. US8071620 (2011).
33. [33] Brandt, E., Angibaud, M.-D. Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase. EP1776358 (2009).
34. [34] Andrianov, V., Dikovska, K., Duffy, J.E.S., Finn, P.W., Gailite, V., Harris, C.J., Kalvinsh, I., Loza, E., Moore, K.G., Piskunova, I., Richie, J., Romero-Martin, M.-R., Starchenkov, I., Vorona, M., Watkins, C.J. Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors. EP2292593 (2011).
35. [35] Cossio, M.F.P., Vara, S.Y.I., San, S.L.E., Otaegui, A.M.D., Masdeu, M.M.M.C., Aldaba, A.M.E., Aginagalde, U.M.M., Villafruela, C.M.S., Alcala, C.M.M.R., Aizepa, O.M. Hydroxyphenyl pyrrole compounds containing and hydroxamic acid as HDAC inhibitors and medicinal applications thereof. EP2508510 (2012).
36. [36] Anandan, S., Xiao, Z.-Y., Patel, D., Ward, J. Inhibitors of histone deacetylase. US7345043 (2008).
37. [37] Xianping, Z., Shan, Y.N. Naphthalene carboxamide derivatives as inhibitors of protein kinase and histone deacetylase, preparation methods and uses thereof. EP2439195 (2012).
38. [38] Bradner, J.E., Mazitschek, R. Histone deacetylase inhibitors. US20100056588 (2010).
39. [39] Lan-Hargest, H.-Y., Wiech, N.L. Novel acetyloxymethyl esters and methods for using the same. US20020119996 (2002).
40. [40] Deziel, R., Leit, S., Beaulieu, P., Chantigny, Y.A., Mancuso, J., Tessier, P., Shapiro, G., Chesworth, R., Smil, D. Dibenzo [b,f][1,4]oxazepin-11-yl-n-hydroxybenzamides as HDAC inhibitors. US20140011988 (2014).
41. [41] Ashwell, M.A., Tandon, M., Namdev, N.D., Lapierre, J.-M., Liu, Y., Wu, H. HDAC Inhibitors. US20100261710 (2010).
42. [42] Lu, X.-P., Li, Z.-B., Ning, Z.-Q. Tricyclic derivatives as potent and selective histone deacetylase inhibitors. US8178577 (2012).
43. [43] Deziel, R., Leit, S., Beaulieu, P., Chantigny, Y.A., Mancuso, J., Tessier, P., Shapiro, G., Chesworth, R., Smil, D. Inhibitors of histone deacetylase. EP2489657 (2013).
44. [44] Kozikowski, A.P., Jung, M., Dritschilo, A., Gaysin, A., Petukhov, P.A., Tueckmantel, W., Yuan, H., Chen, Y. Isoform selective HDAC inhibitors. US8653278 (2014)
45. [45] Berk, S.C., Close, J., Hamblett, C., Heidebrecht, R.W., Kattar, S.D., Kliman, L.T., Mampreian, D.M., Methot, J.L., Miller, T., Sloman, D.L., Stanton, M.G., Tempest, P., Zabierek, A.A. Spirocyclic compounds as HDAC inhibitors. EP1954698 (2009).
46. [46] Heidebrecht, R., Methot, J., Mampreian, D., Miller, T., Siliphaivanh, P. Di-substituted aniline compounds. US8119685 (2012).
47. [47] Venkatramani, C. Cyclo alkyl carbamate benzamide aniline HDAC inhibitor compounds. US8283357 (2012).
48. [48] Müller, M., Müller, B., Maier, T. Sulphonylpyrroles as HDAC inhibitors. EP1725528 (2013).
49. [49] Graupe, M., Venkataramani, C. Alkanoylamino benzamide aniline HDAC inhibitor compounds. US8258316 (2012).
50. [50] Wang, H.-P., Lee, O., Cheng, Y.-W., Wang, C.-L., Chang, F.-S., Hsiao, C.-C. Histone deacetylase inhibitors. EP2388247 (2011).
51. [51] Philip, J., Ontoria, J.M. Heterocycle substituted amide and sulfur amide derivatives as histone deacetylase (HDAC) inhibitors. US20090156619 (2009).
52. [52] Gibson, K.H., Stokes, E.S.E., Waring, M.J., Michael, A.D., Matusiak, Z.S., Maybury, M., Craig, A.R. N-phenyl-4-pyridin-2-ylbenzamide derivatives as histone deacetylase (HDAC) inhibitors for the treatment of cancer. US20100075942 (2010).
53. [53] Maier, T., Beckers, T., Hummel, R.-P., Feth, M., Müller, M., Bär, T., Volz, J. Novel sulphonylpyrroles as inhibitors of HDAC. EP1928872 (2008).
54. [54] Paoletti, F., Romanelli, M.N., Cellai, C., Laurenzana, A., Guandalini, L. S-phenyl-lh-benzo[e][1,4] diazepine substituted with an hydroxamic acid group as potential deacetylase inhibitors. US008324202 (2012).
55. [55] Liu, X., Phillips, A.J., Ungermannova, D., Nasveschuk, C.G., Zhang, G. Macrocyclic compounds useful as inhibitors of histone deacetylases. WO2011150283 (2014).
56. [56] Maier, T., Beckers, T., Hesslinger, C. Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds. EP2100879 (2009).
57. [57] Cossio, M.F.P., Vara, S.Y.I., San, S.L.E., Otaegui, A.M.D., Masdeu, M.M.M. del Carmen, Aldaba, A.M.E., Aginagalde, U.M.M., Villafruela, C.M.S., Alcala, C.M.R.M., Zubia, O.M.A. Hydroxyphenyl pyrrole compounds containing a hydroxamic acid as HDAC inhibitors and medicinal applications thereof. EP2508510 (2012).
58. [58] Guo, L., Tang, G., Wang, Z., Wong, J.C., Zhang, W. Novel Nhydroxy-Benzamids for the treatment of cancer. US20120065204 (2012).
59. [59] Van Duzer, J.H., Mazitschek, R., Ogier, W., Bradner, J.E., Huang, G., Xie, D., Yu, N. Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof. US8148526 (2012).
60. [60] Bradner, J.E., Mazitschek, R. Fluorinated HDAC inhibitors and uses thereof. US20130040998 (2013).
61. [61] Jaeger, F., Drinkuth, S., Ludwig, J., Meyer-Almes, F.-J., Henkes, L. Histone deacetylase (HDAC) inhibiting compounds and method of making same. EP2486923 (2011).
62. [62] Ting-Chao C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-6.
63. [63] Lichenstein, H., Jeffers, M., Xiaozhang, Q., Sehested, M., Petersen, K.D., Ritchie, J. Combination therapy using HDAC inhibitors and erlotinib for treating cancer. EP2502649 (2012).
64. [64] Kozikowski, A., Kalin, J.H., Butier, K.V., Bergman, J., Hancock, W.W. HDAC inhibitors and therapeutic methods using the same. US20140128408 (2014).
65. [65] Yao, T.-P., Sasajima, H., Kawaguchi, Y., Cui, K., Lai, C.-H. Methods of inhibiting cancer cell growth with HDAC inhibitors and methods of screening for HDAC10 inhibitors. US008664182 (2014).
66. [66] Brodie, N., Sabnis, G. HDAC inhibitors and hormone targeted drugs for the treatment of cancer. EP2359828 (2011).
67. [67] McKeown, A.E., Miller, T.A. Pharmaceutical compositions of HDAC inhibitors and chelatable metal compounds, and metal-HDAC inhibitors chelate complexes. US20090239946 (2009).
68. [68] Sabin, R. Adjuvant compositions and methods of potentiating HDAC inhibitors used to treat various diseases. US20130243852 (2014).
69. Noriyuki T, Hisashi N. Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer. Obstet Gynecol Int 2010; Article ID 923824.
70. [70] Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 2011; 7(2): 263-83.
71. Aldana-Masangkay Grace I, Sakamoto Kathleen M. The role of HDAC 6 in cancer. J Biomed Biotechnol 2011; Article ID 875824.
72. [72] Kim H, Bae S. Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 2011; 3(2): 166.
73. [73] Gopalan B, Ponpandian T, Kachhadia V, Bharathimohan K, Vignesh R, Sivasudar V, et al. Discovery of adamantane based highly potent HDAC inhibitors. Bioorg Med Chem Lett 2013; 23(9): 2532-7.
74. [74] Delcuve GP, Khan DH, Davie JR. Targeting class I histone deacetylases in cancer therapy. Expert Opin Ther Targets 2013; 17(1): 29-41.
75. [75] West A, Johnstone R. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014; 124 (1): 30-9.
76. [76] Zhang X, Su M, Chen Y, Li J, Lu W. The design and synthesis of a new class of RTK/HDAC dual-targetted inhibitors. Molecules 2013; 18: 6491-503.
77. [77] Zhanga X, Baoa B, Yua X, Tongb L, Luod Y, Huanga Q, et al. The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase. Bioorg Med Chem 2013; 21: 6981-95.